-
Product Insights
NewJuvenile Macular Degeneration (Stargardt Disease) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Juvenile Macular Degeneration Clinical Trial Report Overview A total of 59 Juvenile Macular Degeneration clinical trials were conducted as of April 2024. The Juvenile Macular Degeneration clinical trial report provides a comprehensive understanding of the Juvenile Macular Degeneration clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gildeuretinol Acetate in Geographic Atrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gildeuretinol Acetate in Geographic Atrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gildeuretinol Acetate in Geographic Atrophy Drug Details: Gildeuretinol acetate (ALK-001) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gildeuretinol Acetate in Juvenile Macular Degeneration (Stargardt Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gildeuretinol Acetate in Juvenile Macular Degeneration (Stargardt Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gildeuretinol Acetate in Juvenile Macular Degeneration (Stargardt Disease)...
-
Product Insights
Juvenile Macular Degeneration (Stargardt Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Juvenile Macular Degeneration (Stargardt Disease) - Drugs In Development, 2023’, provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Sector Analysis
Juvenile Macular Degeneration (JMD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Juvenile Macular Degeneration (JMD) Marketed and Pipeline Drugs Overview JMD, also called juvenile macular dystrophy, is a group of inherited eye disorders that affects children and young adults, disturbing their central vision. JMD is classified into three major types: Stargardt disease, X-linked retinoschisis (juvenile retinoschisis), and Best vitelliform macular dystrophy (Best’s disease). In the 16MM (Australia, Brazil, China, Canada, France, Germany, India, Italy, Japan, Mexico, Russia, South Africa, South Korea, Spain, UK, and the US), epidemiologists estimate there were around...
-
Product Insights
Age Related Macular Degeneration Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Age Related Macular Degeneration Pipeline Drugs Market Overview Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in the depreciation of the macula which may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity, etc. Symptoms include the development of blind spots and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy, and medication such as anti-angiogenic drugs. The Age...
-
Product Insights
Juvenile Macular Degeneration (Stargardt Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Juvenile Macular Degeneration is mostly found in the form of Stargardt disease. Stargardt's disease can occur with symptoms that include blurry or fuzzy vision, dark, empty spots in the center of vision, and difficulty reading or performing detail work. The Juvenile Macular Degeneration (Stargardt Disease) pipeline market research report provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease), complete with analysis...
-
Product Insights
Juvenile Macular Degeneration (Stargardt Disease) Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Juvenile Macular Degeneration (Stargardt Disease) Global Clinical Trials Review, H2, 2017" provides an overview of Juvenile Macular Degeneration (Stargardt Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Juvenile Macular Degeneration (Stargardt Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...